Skip to content

Observation on the Clinical Efficacy of Topical Application of Chubixiaotong Ointment in the Treatment of Knee Osteoarthritis (Wind-Cold-Damp Arthralgia Syndrome)

Observation on the Clinical Efficacy of Topical Application of Chubixiaotong Ointment in the Treatment of Knee Osteoarthritis (Wind-Cold-Damp Arthralgia Syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000294
Enrollment
Unknown
Registered
2026-02-09
Start date
2024-01-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Treatment group:Rheumatism Relief Pain-Relieving Ointment
Control Group:Lorazepam Sodium Gel Paste

Sponsors

Chongqing Dazu District Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for KOA in the 2018 edition of the Osteoarthritis Diagnosis and Treatment Guidelines; (2) Meets the diagnostic criteria for the TCM syndrome type of knee arthralgia-wind-cold-dampness arthralgia; (3) Age between 40 and 70 years, with no restriction on gender; (4) Kellgren-Lawrence imaging grading of I–III; (5) VAS score = 3; (6) No use of nonsteroidal anti-inflammatory drugs, hormones, or topical analgesics for at least 2 weeks prior to enrollment; (7) Voluntary participation and signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with combined rheumatic immune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, etc.; (2) Patients with severe diseases of the cardiovascular, pulmonary, hepatic, gastrointestinal, renal, hematopoietic systems, or tumors, or combined acute or chronic infections or other communicable diseases (hepatitis, tuberculosis, etc.); (3) Patients with local skin damage, infection, or unresolved trauma at the joint being studied; (4) Patients with allergies to any of the study medications; (5) Patients with a history of alcohol abuse, drug use, or neuropsychiatric abnormalities (epilepsy, depression, etc.); (6) Pregnant or breastfeeding women, or those with plans for pregnancy in the near future; (7) Patients currently participating in other clinical drug studies.

Design outcomes

Primary

MeasureTime frame
Pain Intensity VAS Score;

Secondary

MeasureTime frame
WOMAC Osteoarthritis Index;Lequesne Score;

Countries

China

Contacts

Public ContactHu Hao

218, Mid-section of First Ring Road North, Longgang Subdistrict, Dazu District, Chongqing, Chief Physician

1628491894@qq.com13896160948

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026